AU2001238079A1 - Antibody gene therapy with adeno-associated viral vectors - Google Patents

Antibody gene therapy with adeno-associated viral vectors

Info

Publication number
AU2001238079A1
AU2001238079A1 AU2001238079A AU3807901A AU2001238079A1 AU 2001238079 A1 AU2001238079 A1 AU 2001238079A1 AU 2001238079 A AU2001238079 A AU 2001238079A AU 3807901 A AU3807901 A AU 3807901A AU 2001238079 A1 AU2001238079 A1 AU 2001238079A1
Authority
AU
Australia
Prior art keywords
adeno
gene therapy
viral vectors
antibody gene
associated viral
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001238079A
Inventor
Scott Koenig
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MedImmune LLC
Original Assignee
MedImmune LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MedImmune LLC filed Critical MedImmune LLC
Publication of AU2001238079A1 publication Critical patent/AU2001238079A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1027—Paramyxoviridae, e.g. respiratory syncytial virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2848—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta3-subunit-containing molecules, e.g. CD41, CD51, CD61
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Pulmonology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Public Health (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2001238079A 2000-02-09 2001-02-09 Antibody gene therapy with adeno-associated viral vectors Abandoned AU2001238079A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US18231200P 2000-02-09 2000-02-09
US60182312 2000-02-09
PCT/US2001/004150 WO2001059142A1 (en) 2000-02-09 2001-02-09 Antibody gene therapy with adeno-associated viral vectors

Publications (1)

Publication Number Publication Date
AU2001238079A1 true AU2001238079A1 (en) 2001-08-20

Family

ID=22667908

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001238079A Abandoned AU2001238079A1 (en) 2000-02-09 2001-02-09 Antibody gene therapy with adeno-associated viral vectors

Country Status (3)

Country Link
US (1) US20010034062A1 (en)
AU (1) AU2001238079A1 (en)
WO (1) WO2001059142A1 (en)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040136914A1 (en) 1997-10-01 2004-07-15 Dugger Harry A. Buccal, polar and non-polar spray containing ondansetron
US20030082107A1 (en) * 1997-10-01 2003-05-01 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating an infectious disease or cancer
JP4992068B2 (en) 2000-01-27 2012-08-08 メディミューン，エルエルシー Ultra high affinity neutralizing antibody
EP1259547B1 (en) * 2000-03-01 2012-07-11 Medimmune, Inc. High potency recombinant antibodies and method for producing them
US6855493B2 (en) * 2000-11-28 2005-02-15 Medimmune, Inc. Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
US7179900B2 (en) 2000-11-28 2007-02-20 Medimmune, Inc. Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
US20030198624A1 (en) * 2002-03-02 2003-10-23 Mohapatra Shyam S. Method of treating allergic disease and asthma by recombinant adenovirus- and adeno-associated virus- mediated IFN-gamma gene transfer
AU2003223517A1 (en) * 2002-04-09 2003-10-27 Children's Hospital, Inc. Antibody gene transfer and recombinant aav
US7132100B2 (en) 2002-06-14 2006-11-07 Medimmune, Inc. Stabilized liquid anti-RSV antibody formulations
US7425618B2 (en) * 2002-06-14 2008-09-16 Medimmune, Inc. Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
AU2003232081B2 (en) * 2002-07-03 2009-02-05 Brandeis University Central airway administration for systemic delivery of therapeutics
KR100858080B1 (en) * 2002-11-12 2008-09-10 삼성전자주식회사 A method for detecting a PCR product by measuring a electrical signal
EP1812068A4 (en) * 2004-10-29 2010-06-09 Medimmune Inc Methods of preventing and treating rsv infections and related conditions
EP1997830A1 (en) 2007-06-01 2008-12-03 AIMM Therapeutics B.V. RSV specific binding molecules and means for producing them
US8568726B2 (en) 2009-10-06 2013-10-29 Medimmune Limited RSV specific binding molecule
JP6261617B2 (en) 2013-02-14 2018-01-17 ユーシーエル ビジネス ピーエルシー Agents that induce lymphangiogenesis used in the treatment of cystic kidney disease
CN111479916A (en) 2017-10-20 2020-07-31 弗莱德哈钦森癌症研究中心 Systems and methods for generating B cells genetically modified to express selected antibodies
CA3086045A1 (en) 2017-12-19 2019-06-27 Akouos, Inc. Aav-mediated delivery of therapeutic antibodies to the inner ear
AU2018394940A1 (en) * 2017-12-29 2020-08-13 Cornell University Gene therapy for eosinohilic disorders
US20240148903A1 (en) * 2021-03-08 2024-05-09 Nanjing GenScript Biotech Co., Ltd. Delivery of antibody by using dual viral vector system

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5824307A (en) * 1991-12-23 1998-10-20 Medimmune, Inc. Human-murine chimeric antibodies against respiratory syncytial virus
WO1996037234A1 (en) * 1995-05-23 1996-11-28 Thomas Jefferson University Intracellular immunization
JP3948495B2 (en) * 1995-08-24 2007-07-25 ジェネーラ コーポレーション Asthma-related factors as targets for treating atopic allergies, including asthma and related diseases
CA2251738A1 (en) * 1996-04-16 1997-10-23 Immusol Incorporated Targeted viral vectors
US6590079B2 (en) * 1997-01-30 2003-07-08 Ixsys, Incorporated Anti-αvβ3 recombinant human antibodies, nucleic acids encoding same
PT1064393E (en) * 1998-03-20 2005-04-29 Univ Pennsylvania COMPOSITIONS AND METHODS FOR THE PRODUCTION OF RECOMBINANT ADENO-ASSOCIATED VIRUSES WITHOUT AUXILIARY

Also Published As

Publication number Publication date
US20010034062A1 (en) 2001-10-25
WO2001059142A1 (en) 2001-08-16

Similar Documents

Publication Publication Date Title
AU2001238079A1 (en) Antibody gene therapy with adeno-associated viral vectors
AU2001265187A1 (en) Chimeric viral vectors for gene therapy
AU2002248297A1 (en) Aav2 vectors and methods
AU2001236073A1 (en) Gene recombinant antibody and its fragment
AU2002226050A1 (en) Microtiter plate with integral heater
AU4903101A (en) Isolated nucleic acid molecules encoding cancer associated antigens, the antigens per se, and uses thereof
AU1951201A (en) Peptide antigens
AU2001257532A1 (en) Adenoviral vectors for tumor specific gene expression and uses thereof
AU2001229494A1 (en) Chimeric prostate-homing peptides with pro-apoptotic activity
AU2003223517A1 (en) Antibody gene transfer and recombinant aav
AU2001280576A1 (en) Tissue-specific self-inactivating gene therapy vector
AU2002349543A1 (en) Tumor antigens
AU2002251871A1 (en) Muscle-directed gene therapy with aav-1 and aav-6 vectors
AU2002250078A1 (en) Quantitative epstein barr virus pcr rapid assay
AUPR546801A0 (en) Recombinant antibodies
AU2001246703A1 (en) Dna immunization vectors
AU2002347813A1 (en) Chimeric viral vectors for gene therapy
AU2001242625A1 (en) Gene sequence
AU2001288839A1 (en) Self-rearranging dna vectors
AU2001259169A1 (en) Cesert genes, proteins, and modulatory compounds
AU2001294325A1 (en) Hulahoop fixed the winged finger-pressure projection
AU2001227570A1 (en) Isolated nucleic acid molecules encoding cancer associated antigens, the antigens per se, and uses thereof
AU2001234150A1 (en) Novel protein and gene encoding the same
AU6181500A (en) Gene encoding novel tsp1-like protein
AU2001274563A1 (en) Novel polypeptide and its dna